Home › Therapeutic areas › Immunology › Sjögren's Syndrome
Sjögren's Syndrome (6 companies)
Companies with an active program in Sjögren's Syndrome.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | $6.31B | 5 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $864M | 16 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $903M | 7 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 1 | Phase 3 | $1.22B | 2 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
No companies match.